-

BTIG Names Arin Prisand as Head of Corporate Access

NEW YORK--(BUSINESS WIRE)--BTIG announced today the appointment of Arin Prisand as Head of Corporate Access. Ms. Prisand will be responsible for leading BTIG’s robust Corporate Access program and delivering innovative, value-added opportunities that foster meaningful connections between investors and corporate clients.

"Arin’s dynamic background across trading, research sales, and corporate access makes her well-positioned to further elevate BTIG’s platform,” said Christopher Rollins, Global Co-Head of Securities at BTIG. “We look forward to working with her.”

Ms. Prisand brings more than 20 years of experience to the firm. Most recently, she was Head of Corporate Access at Mizuho Americas, where she built and led a high-performing team responsible for global marketing across all event types and sectors. Prior to that, Ms. Prisand worked at Jefferies in both corporate access and equity research sales roles. Earlier in her finance career, she worked on the buy-side at Pequot Capital Management and in equity proprietary trading at Credit Suisse First Boston.

"Arin’s unique perspective from both the buy- and sell-side makes her an ideal leader for our talented Corporate Access team," said Anton LeRoy, Chief Executive Officer of BTIG. "Her deep industry expertise will be invaluable as we continue to invest in our Corporate Access offering and provide our clients with timely, high-quality opportunities."

BTIG’s Corporate Access program hosts client events across the consumer, energy and infrastructure, financials, healthcare, industrials, real estate and technology sectors. For more information about BTIG’s Corporate Access capabilities, please visit www.btig.com.

About BTIG
BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 700 employees, BTIG, LLC and its affiliates operate out of 20 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities. The firm’s core capabilities include global execution, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more.

Disclaimer: https://www.btig.com/disclosures/general-disclaimer/

Contacts

Media Contacts: Jill Gordon
443.668.2055
jgordon@prosek.com

Vanessa Siderow
212.738.6148
vsiderow@btig.com

BTIG


Release Versions

Contacts

Media Contacts: Jill Gordon
443.668.2055
jgordon@prosek.com

Vanessa Siderow
212.738.6148
vsiderow@btig.com

More News From BTIG

BTIG Franchise Sales Adds Healthcare Specialists Bruce Mackle and Dr. Sean Alyeshmerni

NEW YORK--(BUSINESS WIRE)--BTIG announced today the appointments of Bruce Mackle as Managing Director and Sean Alyeshmerni, D.O. as Director within its Franchise Sales team. Both will focus on expanding and strengthening BTIG’s client relationships within the healthcare sector. Bruce Mackle brings over 25 years of healthcare-dedicated financial industry experience on the sell-side, buy-side, and as an investor relations advisor. Over the course of his career at firms including Wells Fargo, UBS,...

BTIG Expands Research Coverage with Appointment of Alex Kania in Utilities and Power

NEW YORK--(BUSINESS WIRE)--BTIG announced today the appointment of Alex Kania as a Managing Director and Senior Research Analyst focused on Utilities and Power Research. This new sector coverage reflects BTIG’s continued investment in research talent and resources, further expanding the firm’s energy and infrastructure practice. Mr. Kania will spearhead coverage of electric, natural gas and water utilities— providing actionable insights to institutional investors navigating today’s evolving ene...

BTIG to Host Virtual Biotechnology Conference on July 29-30, 2025

NEW YORK--(BUSINESS WIRE)--BTIG announced today that it will hold its annual Biotechnology Conference on Tuesday, July 29th through Wednesday, July 30th, 2025. The virtual event will host over 70 established and emerging healthcare company management teams for one-on-one investor meetings and thematic panel discussions with industry leaders. Panel themes will include lupus, pulmonary hypertension, emerging trends in inflammatory bowel disease and irritable bowel syndrome, latest developments in...
Back to Newsroom